UNLOXCYT gains expanded US cancer-guideline status

Business Updates View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹1743.00

prior close

₹1753.00

announcement price

After-mkt

timing

Nifty 100market-0.6%+0.7% vs market

Pharmaceuticals peers, median of 172sector-1.7%+1.8% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty 100 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.1

15m

-0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1-0.6+0.7-1.7+1.8

Next day

+0.9-1.1+1.9-2.2+3.1

+0.3-1.8+2.1-3.5+3.8

-0.3-1.1+0.8-2.4+2.1

+0.5-0.9+1.3-1.2+1.7

+0.8pendingpending+0.1+0.8

—————

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma said UNLOXCYT (cosibelimab-ipdl) was added as a Category 2A recommended option in US cancer-care guidelines for locally advanced cutaneous squamous cell carcinoma when curative surgery or radiation is not possible. This follows a similar 2025 status in metastatic disease. The drug was already US FDA-approved in 2024. The study showed a 55% response rate, including 26% complete responses, with 24.1 months of median follow-up.

Likely market impact

Broader guideline recognition may improve US physician adoption and patient access, supporting UNLOXCYT sales. No financial impact was disclosed.